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Abstract
CTCF is a highly conserved, multifunctional zinc finger protein involved in critical aspects of gene regulation including
transcription regulation, chromatin insulation, genomic imprinting, X-chromosome inactivation, and higher order chromatin
organization. Such multifunctional properties of CTCF suggest an essential role in development. Indeed, a previous report
on maternal depletion of CTCF suggested that CTCF is essential for pre-implantation development. To distinguish between
the effects of maternal and zygotic expression of CTCF, we studied pre-implantation development in mice harboring a
complete loss of function Ctcf knockout allele. Although we demonstrated that homozygous deletion of Ctcf is early
embryonically lethal, in contrast to previous observations, we showed that the Ctcf nullizygous embryos developed up to
the blastocyst stage (E3.5) followed by peri-implantation lethality (E4.5–E5.5). Moreover, one-cell stage Ctcf nullizygous
embryos cultured ex vivo developed to the 16–32 cell stage with no obvious abnormalities. Using a single embryo assay that
allowed both genotype and mRNA expression analyses of the same embryo, we demonstrated that pre-implantation
development of the Ctcf nullizygous embryos was associated with the retention of the maternal wild type Ctcf mRNA. Loss
of this stable maternal transcript was temporally associated with loss of CTCF protein expression, apoptosis of the
developing embryo, and failure to further develop an inner cell mass and trophoectoderm ex vivo. This indicates that CTCF
expression is critical to early embryogenesis and loss of its expression rapidly leads to apoptosis at a very early
developmental stage. This is the first study documenting the presence of the stable maternal Ctcf transcript in the
blastocyst stage embryos. Furthermore, in the presence of maternal CTCF, zygotic CTCF expression does not seem to be
required for pre-implantation development.
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Introduction
CTCF (CCCTC-binding factor) is a highly conserved, ubiqui-
tously expressed 11 Zn finger DNA binding protein that was
originally identified as a factor interacting with specific sequences
in the c-myc gene promoters [1,2,3]. CTCF utilizes different
combinations of its Zn- fingers to bind a relatively large number of
highly divergent target sequences throughout genome [3,4,5,6,7].
CTCF was originally characterized as a transcription factor
involved in repression [2,3,8,9] or activation of transcription
[10,11], but its activity has now been extended to include a variety
of other roles in gene regulation, including chromatin insulation
[4,12,13]. Indeed, genomic regions displaying chromatin insulator
activity harbor CTCF binding sites, and CTCF binding is
required for their insulator activity [6,14,15,16]. Moreover, CTCF
binding has been shown to mark boundaries between distinct
chromatin domains in the genome [6,17,18]. Methylation-
sensitive CTCF binding plays a critical role in regulating genomic
imprinting at several genomic loci, including the Igf2/H19 locus
[19,20,21,22]. In addition CTCF plays an important role in X-
chromosome inactivation [23,24], and genes which escape X-
inactivation are separated from stably inactivated X-chromosome
genes by CTCF binding sites [25]. CTCF has also been shown to
be involved in organizing higher order chromatin structure
including the interchromosomal association of transcriptionally
active genes [12,13,26].
Given the multifunctional nature of CTCF in regulating gene
expression and a recent report on the essential function of CTCF
in pre-implantation development using the oocyte-specific RNAi
approach [27], we wished to determine what effect a complete loss
of zygotic CTCF expression would have on embryogenesis.
Accordingly, we engineered mice harboring a complete loss of
function Ctcf allele. While mice heterozygous for this allele
appeared phenotypically normal, nullizygous mice displayed early
embryonic lethality at the peri-implantation stage. Interestingly,
Ctcf nullizygous embryos appeared morphologically normal up to
the blastocyst stage of development, which was associated with
expression of the maternal wild type Ctcf transcript and protein.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34915Subsequent loss of this stable maternal transcript was temporally
associated with loss of CTCF protein expression, apoptosis and
embryonic lethality.
Results
Generation of Ctcf (+/2) mice
We previously observed that the coding region of CTCF exhibits
marked (.93%) evolutionary conservation in chickens, mice and
humans [3], and we therefore utilized a human CTCF cDNA
probe to clone the mouse Ctcf genomic locus. Utilizing the Jackson
Laboratory Interspecific Backcross DNA Panels [28] together with
a polymorphic CAA repeat marker that we identified in the second
intron of the mouse Ctcf locus, we mapped Ctcf to a single locus in
distal mouse chromosome 8 (Figure 1). Subsequently we observed
that the Ctcf locus in mouse (Figure 2A) and human [5,29] has a
virtually identical exon/intron structure consisting of two non-
coding and ten coding exons.
Our efforts to engineer Ctcf knockout mice via homologous
recombination in mouse embryonic stem (ES) cells are detailed in
Materials and Methods. We first isolated the mouse Ctcf genomic
locus from a 129sv mouse genomic library, engineered a targeting
vector from the Ctcf genomic clones and used this vector to
generate a null allele (Figure 2A). We chose to generate an allele
that deleted all coding exons of Ctcf since only partial deletion may
result in production of an aberrant CTCF protein arising from
internal cryptic translation initiation sites and alternative splicing.
The linearized targeting vector was electroporated into ES cells,
and positive recombination was scored by Southern blots with the
designated 5-prime and 3-prime probes located outside of the
targeting cassette (Figure 2A, B). Seven positive ES clones were
selected to produce chimeric mice and two clones of Ctcf (+/2)
heterozygous knockout mice were established, as confirmed by the
presence of both the wild type and deleted Ctcf alleles documented
by Southern blot hybridization of EcoRV-digested tail genomic
DNA (Figure 2B). To excise the neo cassette, one clone (5-3) of Ctcf
(+/2) heterozygous knockout mice was crossed to the MORE
(Mox2Cre) mice, which express the Cre recombinase from the
Mox2 locus [30]. The resulting neo-excised Ctcf allele was
documented by PCR using primers flanking the remaining LOX
site shown in Figure 2A.
Deletion of the Ctcf locus in the Ctcf knockout allele was also
confirmed utilizing a FISH assay on metaphase chromosomes
from lymphocyte cultures derived from Ctcf (+/2) and Ctcf (+/+)
mice (Figure 2C). As a Ctcf probe we utilized a 17 kb lambda Ctcf
genomic clone (19.1) containing all of the coding exons that were
deleted in the Ctcf knockout allele (Figure 2A). As a positive control
we used a centromeric probe from mouse chromosome 8 where
Ctcf maps (170 kb BAC clone MGB 11301). The Ctcf probe was
visualized with fluorescein (green) and centromeric probe for
chromosome 8 was visualized with Cy3 (red). Only a single
chromosome from the Ctcf (+/2) metaphase spreads displayed a
Ctcf signal, while two signals were clearly seen in similar spreads
from the Ctcf (+/+) mice (Figure 2C).
Ctcf knockout mice exhibit embryonic lethality
To study the effect of CTCF knockout on embryonic
development, we generated the Ctcf (+/2) heterozygous mice by
crossing C57/BL6 Ctcf (+/+) mice to 129sv Ctcf (+/2) mice. The
C57BL6/129sv F1 Ctcf (+/2) mice were viable and displayed no
apparent phenotypic abnormalities. However, when intercrossing
heterozygotes we observed a selective absence of Ctcf (2/2) pups
in the newborn offspring (Table 1, top row) indicating that the
absence of functional CTCF is lethal to the developing embryo.
To determine at what stage of embryonic development this
lethality occurs we genotyped embryos obtained at different stages
of development following the breeding of Ctcf (+/2) heterozygotes.
For this genotyping we utilized a multiplex PCR- based assay that
distinguishes the wild type from mutant Ctcf alleles (Figure 3B). We
observed a Mendelian ratio of genotypes at embryonic day 3.5
(E3.5) (Table 1). Ctcf (2/2) E3.5 blastocysts had a distinct
blastoceal and intact zona pellucida, displaying no phenotypic
abnormalities compared with their wild type or heterozygous
littermates (Figure 4A). However, no Ctcf (2/2) embryos were
observed at embryonic day 5.5 (E5.5) and beyond (Table 1).
Notably, the number of empty deciduae in E5.5–6.5 heterozygous
intercrosses was markedly increased in comparison to control
crosses (Table 2). Taken together our data indicate that the Ctcf
(2/2) embryos fail to implant and become non-viable between
E4.5 and E5.5.
Ctcf (2/2) embryos reach the blastocyst stage but fail to
develop further, which is associated with the loss of the
maternal Ctcf mRNA and CTCF protein
To gain further insight into the embryonic defects resulting
from the absence of CTCF we isolated newly fertilized eggs from
Ctcf heterozygous crosses, cultured these embryos ex vivo and then
genotyped them. Cultures of explants from E0.5 one cell stage Ctcf
Figure 1. Ctcf maps to mouse chromosome 8. The Jackson
Laboratory interspecific backcross panels (BSS and BSB) [28] were
utilized to map the Ctcf locus to mouse chromosome 8. The loci are
listed in order with the most proximal at the top. The black boxes
represent the C57BL6/JEi allele and the white boxes the SPRET/Ei allele.
The number of animals with each haplotype is given at the bottom of
each column of boxes. The percent recombination (R) between
adjacent loci is given to the right of the lower figure together with
the standard error (SE) for each R.
doi:10.1371/journal.pone.0034915.g001
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34915Figure 2. Generation of Ctcf knockout mice. (A) A schematic diagram of the mouse Ctcf locus and the targeting vector derived from the wild
type Ctcf allele as described in Materials and Methods are shown. E1–E12 denote Ctcf exons 1 through 12. Restriction enzyme sites shown on map are
as follows: E denotes EcoRI, X denotes XbaI, and S denotes SpeI. The locations of both the 5-prime and 3-prime Ctcf genomic probes for the Southern
blot analysis are indicated. Red arrows show the locations of genotyping primers. A schematic diagram of genomic digest with EcoRV of the Ctcf
knock-out and wild type alleles is shown below. (B) A Southern blot analysis of EcoRV digested genomic DNA utilizing the 5-prime and 3-prime Ctcf
genomic probes distinguishes the wild type (14 kb or 25 kb) from the mutated (8 kb or 13 kb) Ctcf alleles. (C) FISH analysis of chromosome spreads
from lymphocyte cultures derived from Ctcf heterozygous (+/2) and wild type (+/+) mice. The probe for Ctcf, a lambda phage clone 19.1 containing a
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many embryos successfully reaching the 32 cell blastocyst stage
within four days (Figure 3A and Table 3). We observed no gross
phenotypic abnormalities in the cultured pre-implantation stage
Ctcf (2/2) embryos compared with their wild type or heterozy-
gous littermates.
To confirm the absence of CTCF expression in the Ctcf (2/2)
E3.5 blastocyst stage embryos, we developed a single embryo assay
that allowed both genotyping and mRNA expression analysis of
the same embryo as detailed in Materials and Methods. For both
genotyping and RT-PCR, we utilized multiplex PCR conditions to
control for quality of genomic DNA and cDNA, respectively.
Unexpectedly, RT-PCR analysis of mRNA extracted from E3.5
blastocyst stage embryos isolated from Ctcf (+/2) intercrosses
revealed Ctcf transcripts not only in the Ctcf (+/+) and (+/2)
embryos but also in the Ctcf (2/2) embryos (Figure 3B, left panel).
In contrast, we could not detect any Ctcf transcripts in the freshly
isolated E4.5 stage Ctcf (2/2) embryos (Figure 3B, right panel).
These observation were confirmed utilizing a quantitative real-
time RT-PCR assay of the Ctcf (+/+), (+/2), and (2/2) embryos
(Figure 3C). The presence of the Ctcf mRNA in the Ctcf (2/2)
blastocyst stage embryos likely represents the retention in the
developing embryo of the maternal oocyte Ctcf transcripts that
appear to remain up to E3.5 stage of development but are lost by
E4.5. Although we found it technically difficult to perform both
Ctcf mRNA quantitation and anti-CTCF immunohistochemistry
on the same embryo, we observed that all (16/16) E3.5 embryos
from Ctcf heterozygous intercrosses were positive by immunohis-
tochemistry for CTCF protein expression (Figure 4B). The chance
that none of these 16 embryos were Ctcf (2/2) according to the
expected Mendelian ratio of genotypes is less than 0.05. This
strongly suggests that the Ctcf mRNA present in the E3.5 Ctcf (2/
2) embryos is indeed associated with CTCF protein expression.
To gain further insight into the mechanism of early embryonic
lethality of the Ctcf (2/2) embryos, we isolated E3.5 blastocyst
stage embryos from Ctcf heterozygous intercrosses and cultured
them ex vivo. The cultured embryos were then PCR genotyped and
assessed for Ctcf transcript expression utilizing RT-PCR. We
observed that while the ex vivo cultures of the Ctcf (+/+) and (+/2)
E3.5 stage embryos actively proliferated over 2–4 days to form an
inner cell mass and trophoectoderm (Figure 4A, top panel), the
Ctcf (2/2) E3.5 embryos explants failed to outgrow and the inner
cell mass and trophoectoderm did not develop (Figure 4A, bottom
panel). While both Ctcf transcripts and CTCF protein were
observed in the Ctcf (2/2) E3.5 blastocyst stage embryos
(Figure 3B,C and Figure 4B), following 2 days of ex vivo culture
these embryos no longer expressed Ctcf mRNA or protein (data not
shown and Figure 4C). Apoptosis as assessed by TUNEL assay was
much more pronounced in the cultured Ctcf (2/2) blastocysts
compared with the cultured Ctcf (+/+) blastocysts (Figure 4C).
Discussion
The ubiquitous expression of CTCF, its marked evolutionary
conservation and its central role in controlling gene expression by
regulating DNA methylation, genomic imprinting, insulator
activity, and interchromosomal associations [4,5,12,13] suggests
that it may be a crucial regulator of cell viability, proliferation, and
differentiation. This is indeed confirmed in the present study in
which we observe that mouse embryos nullizygous for Ctcf become
arrested in development very early in embryogenesis. Embryos
undergo initial cell division and reach the blastocyst stage (E3.5).
However, these Ctcf nullizygous embryos appear incapable of
uterine implantation and invariably undergo extensive apoptosis
between E4.5 and E5.5.
Given the recently documented essential role for CTCF in pre-
implantation development [27,31], together with the previous
observation that conditional loss of CTCF expression in cell
culture is associated with the rapid onset of apoptosis [32,33], it is
perhaps surprising that the Ctcf nullizygous embryos are even
capable of repeated cell division to reach the 32 cell blastocyst
stage. We clearly demonstrate here that this initial cell prolifer-
17 kb Ctcf genomic DNA insert that includes all coding Ctcf exons that were deleted in the Ctcf knockout allele (Figure 2A), was visualized with
fluorescein (green fluorescence). The probe for chromosome 8 identification, a BAC clone (MB11301, Research Genetics), was visualized with Cy3 (red
fluorescence). Examples of single metaphase cells from the Ctcf (+/2) and Ctcf (+/+) mice after hybridization to the Ctcf and chromosome 8 probes
are shown. Both homologues of chromosome 8 are labeled with a red and a green signal in the wild type mouse, whereas absence of green signals
on one homologue of chromosome 8 confirmed the presence of a deletion of Ctcf in the Ctcf (+/2) mouse.
doi:10.1371/journal.pone.0034915.g002
Table 1. Ctcf nullizygous mice display early embryonic lethality.
Cross Stage Average number of pups or embryos per cross Ctcf genotype
Female6Male +/+ +/2 2/2
(+/2)6(+/2) Postnatal 7.2 39 84 0
(+/2)6(+/+)* Postnatal 7.1 29 27 NA
(+/+)6(+/2)* Postnatal 7.4 18 19 NA
(+/2)6(+/2) E12.5 7.5 4 11 0
(+/2)6(+/2) E10.5 8.1 8 16 0
(+/2)6(+/2) E8.5 7.6 13 26 0
(+/2)6(+/2) E6.5 8 10 24 0
(+/2)6(+/2)E 5 . 5 7 6 1 4 0
(+/2)6(+/2) E3.5 8.5 18 34 14
*Control crosses.
NA=not applicable.
doi:10.1371/journal.pone.0034915.t001
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with the retention of the wild type maternally-derived Ctcf
transcript at the preimplantation stage. Maternal transcripts in
general are well documented to be present in the embryo up to the
two-cell stage, when the zygotic transcription is activated, however
recent evidence suggests that certain maternal transcripts are still
retained up to the blastocyst stage [34,35,36]. In fact, many
embryonically lethal null mutations are believed to be masked by
prolonged maternal expression of the genes and therefore rarely
result in early cleavage-stage pre-implantation lethality [37,38,39].
Indeed, we reproducibly detected Ctcf maternal transcripts in the
Ctcf nullizygous blastocysts corresponding to E3.5 (Figure 3B,C),
suggesting that the presence of this wild type transcript may be
involved in maintaining the viability of the Ctcf (2/2) embryo
during pre-implantation development. Consistent with this
hypothesis, we observed that by E4.5 stage of development, the
Ctcf maternal transcript is no longer detected in the Ctcf nullizygous
embryos, and this is temporally associated with the onset of
apoptosis.
In mammals, the transition between oocyte and embryo
development occurs in the absence of active transcription and
depends on the presence and coordinated translation of stored
mRNAs transcribed in the growing oocyte [40,41,42]. The
stability and translation of such maternal transcripts was found
to correlate with the presence of cytoplasmic polyadenylation
elements (CPE) within about 90–120 nucleotides 5-prime of the
nuclear polyadenylation signal, AAUAAA [43]. Consistently,
cytoplasmic polyadenylation of some maternal transcripts was
shown to be necessary for oocyte maturation and initiation of pre-
implantation development in the mouse [44]. Several RNA-
binding proteins including the CPE-binding protein (CPEB) were
shown to bind CPEs to form a translation-repressing complex that
upon activation would release the mRNA allowing formation of
the initiation complex [41,45,46]. The CPE was originally
identified as an UUUUAU sequence in 3-prime UTRs of
maternal transcripts. Survey of 3-prime UTRs of a series of
maternal mRNAs that are relatively abundant in the mouse oocyte
and zygote expanded this consensus to (A)UUUU(UU)A(UAA)
[43]. In our study, we identified a stable maternal Ctcf mRNA that
Figure 3. Ctcf (2/2) embryos retain maternal Ctcf mRNA and develop to the blastocyst stage. (A) E0.5 one-cell stage embryos were
isolated from Ctcf (+/2) heterozygous intercrosses and cultured ex vivo as detailed in Materials and Methods. (B) A single embryo assay shows
genotyping and RT-PCR analysis of DNA and RNA simultaneously isolated from the same freshly isolated E3.5 and E4.5 pre-implantation stage
embryos. The top panel shows a representative multiplex PCR-based genotyping analysis of genomic DNA from these embryos, which distinguishes
wild type and mutated Ctcf alleles. The next panel shows multiplex RT-PCR analysis of mRNA from the same pre-implantation embryos for the
presence of Ctcf and Gapdh transcripts. The bottom panel shows ‘no RT’ controls for the same samples. The displayed results are representative of
over 60 pre-implantation embryos that were analyzed from intercrosses of Ctcf (+/2) heterozygous mice. HaeIII digested QX DNA was utilized as DNA
molecular weight markers in these gels. (C) Real time RT-PCR analysis of Ctcf expression was performed on genotyped E3.5 and E4.5 embryos from
Ctcf (+/2) heterozygous intercrosses. Ctcf RNA levels were normalized to Gapdh expression. The results represent the mean of 3–6 independent
embryos of the indicated genotype. Each embryo was assayed in triplicate, data represents mean +/2 standard error.
doi:10.1371/journal.pone.0034915.g003
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Cross Total # of deciduae Ctcf genotype of embryos # of empty deciduae
Female Male +/+ +/2 2/2
Heterozygous crosses
+/2 +/2 72 16 38 0 18
Control crosses
+/2 +/+ 15 6 9 NA 0
+/++ /2 23 7 15 NA 1
NA=not applicable.
doi:10.1371/journal.pone.0034915.t002
Figure 4. Ctcf nullizygous embryos fail to develop beyond the E3.5 stage and undergo apoptosis. (A) Ex vivo outgrowth of E3.5 embryos.
Blastocysts (E3.5) were isolated from Ctcf heterozygous (+/2) intercrosses and cultured ex vivo for the indicated number of days. At the end of the
culture period the embryos were harvested and PCR genotyping and RT-PCR performed. The cultured Ctcf (+/+) and (+/2) embryos outgrew to form
an inner cell mass (ICM) and trophoectoderm (TE) while little proliferation was noted in the cultured Ctcf (2/2) embryos (406). (B) E3.5 blastocyst
stage embryos isolated from the indicated crosses were subjected to DAPI staining and anti-CTCF immunochemistry (406). All (16/16) embryos
analyzed from the Ctcf (+/2) heterozygous intercrosses were positive for CTCF protein expression, displaying staining patterns similar to the two
representative embryos shown here. The expected Mendelian ratio of genotypes in such crosses indicates that the chance that none of these 16
embryos were Ctcf (2/2) is less than 0.05 (i.e. (3/4)
16>0.01). (C) Day two outgrowths of E3.5 embryos of the indicated genotype. Blastocysts (E3.5)
were cultured ex vivo for two days and then subjected to DAPI staining, anti-CTCF immunohistochemistry and TUNEL assay (406). Ctcf (+/+) and (+/2)
embryos outgrew and expressed CTCF, while cultured Ctcf (2/2) embryos failed to outgrow and exhibited loss of CTCF protein expression and
increased apoptosis. The observations displayed here involve one Ctcf (+/+) and two Ctcf (2/2) embryos cultured ex vivo and are representative of
over 60 embryos that were analyzed from Ctcf (+/2) heterozygous intercrosses.
doi:10.1371/journal.pone.0034915.g004
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implantation stage, suggesting that Ctcf transcripts might have a
potential CPE element in its 3-prime UTR. Indeed, a CPE-like
sequence, AUUAUUUUA, is located ,80 nt upstream from a
classic nuclear polyadenylation signal AAUAAA in the mouse Ctcf
mRNA. Moreover, this potential CPE in Ctcf 3-prime UTR is
100% conserved between mouse (NCBI Accession Number:
NM_181322) and human (NCBI Accession Number:
NM_006565).
Maternal-effect genes are usually transcribed in oocytes and
essential for early embryonic development [47,48,49,50]. Chro-
matin structure has been shown to be important for reprogram-
ming gene expression during zygotic genome activation (ZGA) in
pre-implantation development [38,51,52,53]. Perhaps it is not
surprising that CTCF that is involved in chromatin insulation and
organization of higher order chromatin structure was found to be
highly expressed in both oocytes and pre-implantation embryos
[21,27,54]. Moreover, a recent transgenic study using the oocyte-
specific Ctcf RNAi approach [27] demonstrated its essential role in
pre-implantation development suggesting that Ctcf may also be a
maternal-effect gene. The authors reported that maternal
depletion of CTCF resulted in both meiotic defects in oocyte
development and mitotic defects in the embryo and that mitotic
defects and apoptosis occurred at an earlier embryonic develop-
mental stage (morula) than we observed (peri-implantation). This
apparent discrepancy between the previous and our present work
can be readily explained by the completely different technical
approaches utilized in these studies. The previous RNAi-based
approach would likely have efficiently depleted both maternal and
zygotic Ctcf mRNA, likely resulting in earlier apoptosis. Thus these
previous experiments did not clearly distinguish between the
effects of maternal and zygotic expression of CTCF on pre-
implantation development. Our present study, which utilizes a
genetic knockout of the Ctcf locus, would not have affected the
maternal Ctcf mRNA, which likely prolonged the viability of the
embryo beyond the morula to the blastocyst stage. Thus our
present observations clearly demonstrate that in the absence of the
zygotic expression of CTCF, stable maternal Ctcf transcripts are
sufficient to maintain pre-implantation development of the
embryo, establishing Ctcf as a maternal-effect gene.
Materials and Methods
Ethics Statement
This study involved mice that were bred and housed in the
centralized AAALAC accredited Fred Hutchinson Cancer Re-
search Center Animal Facilities. All experimental procedures were
performed in compliance with and approved by the Fred
Hutchinson Cancer Research Center Institutional Animal Care
and Use Committee (IACUC) protocol # 1271. Animals were
euthanized humanely by carbon dioxide overdose as recom-
mended by the Panel of Euthanasia of the American Veterinary
Medical Association (AVMA).
Chromosome mapping of the mouse Ctcf gene
The chromosomal location of Ctcf was determined by using the
Jackson Laboratory interspecific backcross panels: (C57BL/6J6M.
spretus) F16C57BL/6J, called Jackson BSB, and (C57BL/
6JEi6SPRET/Ei) F16SPRET/Ei, called Jackson BSS [28]. A
polymorphic region encompassing a simple sequence repeat
located in the second Ctcf intron was used to distinguish between
the C57BL/6J and the M. spretus Ctcf alleles. PCR primers used to
amplify this region include: Forward: 59 CCA GGA GAG CCA
AGG ATA TAT AGT GAG ACC 39 and Reverse: 59 GGT TAG
GAT TAC AGT GTA CAT CAC CAT ACC 39 with a product
size of 320 bp for the C57BL/6J Ctcf allele and 340 bp for the M.
spretus allele.
Targeted disruption of the Ctcf locus
The mouse Ctcf genomic locus was isolated from a 129sv mouse
genomic library and overlapping lambda genomic clones encom-
passing all coding exons of Ctcf were mapped and partially
sequenced. To make the targeting vector (Figure 2A) we employed
a three-step ligation strategy. First the ‘‘left arm’’, a 3.5 kb EcoR1
fragment from the lambda clone 4.12 was cloned into pZErO
(Invitrogen), then the Not1-Apa1 fragment from the pPGKneob-
paAlox2PGKDTA plasmid (from Phil Soriano) was cloned into
pZero3.5EE, resulting in pleftArm plasmid. Finally the ‘‘right
arm’’, a 2.6 kb SpeI fragment from the lambda clone 13.2 was
ligated into a compatible and unique Nhe1 site of the pLeftArm
plasmid. This targeting construct harbors the PGK-neo cassette
for positive selection and a PGK-DTA toxin expression cassette
for negative selection. This linearized vector was electroporated
into ES cells, and positive recombination was scored by Southern
blots with the designated 5-prime and 3-prime probes located
outside of the targeting cassette (Figure 2A, B). ES clones, positive
for the wild type and mutated Ctcf EcoRV fragments, were selected
to produce chimeric mice (Figure 2B). To excise the neo cassette,
the Ctcf (+/2) heterozygous knockout mice were crossed to the
MORE (Mox2Cre) mice, which express Cre recombinase from
Mox2 locus [30]. The resulting neo-excised Ctcf allele was
documented by PCR using primers flanking the remaining LOX
site as described under Genotyping. The heterozygous Ctcf (+/2)
mice were backcrossed to 129sv genetic background. For
embryonic lethality studies, the C57BL6/129sv F1 Ctcf (+/2)
mice were generated by crossing C57/BL6 Ctcf (+/+) mice to
129sv Ctcf (+/2) mice.
FISH analysis
Metaphase chromosomes preparations were obtained from
mice heterozygous for the Ctcf deletion and from control wild type
mice. Spleens were dissected from the mice and short-term
lymphocyte cultures were stimulated by lipopolysaccharide.
Chromosome preparations were harvested using 0.75 M KCl
and methanol: acetic acid (3:1). Slides were denatured as described
previously [55]. A 17 kb Ctcf genomic DNA fragment cloned in
lambda phage (lambda 19.1, Figure 2A) was labeled with biotin by
nick-translation using a Bionick kit from Invitrogen. A 170 kb
BAC clone (MB11301, Research Genetics) used to mark the
proximal region of mouse chromosome 8 was labeled with
digoxygenin by nick-translation. Both probes were hybridized in
the presence of mouse Cot1 DNA and of lambda phage DNA.
Hybridization and washes were done as described previously [55].
The biotin-labeled Ctcf probe was revealed by an anti-biotin
antibody made in goat followed by an anti-goat antibody labeled
Table 3. Ctcf nullizygous embryos can develop ex vivo to the
morula/blastocyst stage.
Ctcf genotype 1–8 cell Morula/Blastocyst Total
+/+ 67 1 3
+/2 or 2/+ 10 18 28
2/2 54 9
doi:10.1371/journal.pone.0034915.t003
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vealed the digoxygenin-labeled M11301 probe. Slides were stained
with Hoechst and actinomycin D and signals examined by
fluorescence microscopy.
Ex vivo culture of pre-implantation stage embryos
All mouse studies were approved by the local Institutional
Animal Care and Use Committee (IACUC) and all efforts were
made to minimize suffering. Ctcf heterozygous intercrosses
produced an average of 8–9 pre-implantation stage embryos per
mating. All embryos collected were from natural matings without
the use of hormone-stimulated super-ovulation. To isolate E0.5
one cell-stage embryos, mice on the day of cervical plug formation
were sacrificed, and under an inverted microscope the egg sac was
dissected from the oviduct and incubated briefly in M2 media
(Specialty Media) plus hyaluronidase (100 ug/ml) to remove the
cumulus layer as previously described [56]. The fertilized eggs
were then isolated and cultured individually in 100 ul droplets of
M16 media (Specialty Media) in 35 mm Petri dishes flooded with
mineral oil. For the culture of E3.5 blastocyst stage embryos, mice
were sacrificed three days after cervical plug formation and the
uterus flushed with DMEM supplemented with 10% FBS. Under
the inverted microscope, individual blastocysts were isolated and
then cultured on pre-coated 0.1% gelatinized 6-well plates in
DMEM, 10% FBS, and LIF (Leukaemia Inhibitory Factor,
ESGRO, 1000 U/ml, Millipore) in a 37C incubator with 5%
CO2. DNA and RNA was extracted from the freshly isolated or ex
vivo cultured embryos.
Genotyping and RT-PCR analysis of pre-implantation
stage embryos
DNA and mRNA were simultaneously extracted from the
freshly isolated or ex vivo cultured pre-implantation stage embryos
using the modified DNA/RNA extraction protocol using the
Dynal Dynabeads (Invitrogen). Briefly, pre-implantation stage
embryos were collected in a drop of M2 media, rinsed in RNAse
Away solution (Molecular Bioproducts) and then placed in 10 ul of
the ‘cleared Dynabeads solution’ (DNA lysis buffer) for DNA
processing according to the Dynabeads DNA Direct Universal kit
protocol (Invitrogen). Following the lysis of the embryo and the
DNA/Dynabeads complex formation using 170 ul of the resus-
pended Dynabeads per embryo, the supernatant was transferred to
a clean, pre-chilled tube with 100 ul of the RNA lysis buffer from
the Dynabeads mRNA Direct Kit (Invitrogen) and stored on ice
for mRNA extraction until the DNA processing was complete.
mRNA extraction was carried out using Oligo(dT)25 Dynabeads
according to the mRNA Direct Kit protocol (Invitrogen).
For genotyping, the DNA was subjected to multiplex PCR
utilizing primer sets recognizing the mutated and wild type Ctcf
alleles. The primer pair for the wild type Ctcf allele is the following:
Forward: 59 GAG AAA GTA GTT GGT AAT ATG AAG CCT
CC 39 and Reverse: 59 GGA CAT GTG TAA CTG CAA AGC
TCA CAC TG 39, with a product size of 420 bp. The primer pair
identifying the knockout Ctcf allele includes: Forward: 59 GGC
ATG CTG GGG ATG CGG TGG GCT CTA TGG 39 and
Reverse: 59 CCA GTG CCC TCT GAT ACA TGA TTG TGA
TCC 39, with a product size of 600 bp. Neo-excised allele
genotyping primers are: Forward: 59 TGA CCT AAC CCT AAC
CCT AGC TGA 39 and Reverse: 59 TGA AAC TGA CTC TGA
GCA AAG GGA 39, with a product size of 516 bp.
For standard RT-PCR analysis the mRNA extracted from the
embryos was reversed transcribed utilizing Superscript III
(Invitrogen) under the following conditions. Random hexamers
were added to 1–3 mg of RNA and incubated at 70uC for
5 minutes in a thermocycler. The temperature was cycled to 50uC
and the RNA/primer mixture equilibrated for 5 minutes. Next,
the reaction mixture (nuclease free H2O, 56 buffer, RNase
inhibitor, dNTPs, DTT, and RT, except for no RT control), pre-
equilibrated at 50uC, was added to the RNA/primer mixture and
incubated for two hours at 50uC, followed by heat inactivation at
70uC for 5 minutes. Ctcf expression was analyzed using multiplex
PCR conditions for both Ctcf and control Gapdh transcripts.
Primers for the Ctcf transcript (GENBANK U51037.1) included:
Sense: 59 GAG CCT GCT GTA GAA ATT GAA CCT GAG
CC 39, (2188–2216) and Antisense: 59 CCA ATA GTC CTG
GTG CCG AGC AAG GCC CC 39, (2551–2522) with a product
size of 363 bp spanning Ctcf exons 11 and 12. Primers for the
control Gapdh transcript included: Sense: 59 CGT ATT GGG
CGC CGT GTC ACC AGG GC 39, and Antisense: 59 GCC
ATG AGG TCC ACC ACC CTG TTG CTG 39, with a product
size of 950 bp. RNA was tested for DNA contamination using a
no-RT control and primers were verified by amplification of
genomic DNA. The exact PCR conditions are available upon
request.
For the real time RT-PCR analysis, cDNA was generated with
SuperScript II reverse transcriptase (Invitrogen) under the
following conditions. Random hexamers were added to 1.5 ug of
RNA and incubated at 75uC for 5 min then transferred
immediately to ice. Next, the reaction mix including 56
SuperScript II buffer, 0.1 M DTT, RNase inhibitor, dNTPs,
and SuperScript II RT was added to the RNA/primer mixture
and incubated at 45uC for 1 hour, then 50uC for 10 min, followed
by heat inactivation at 75uC for 15 min. Real Time PCR analysis
was performed on the automated ABI 7900 PCR machine
(Applied Biosystems) using TaqMan Universal PCR Master Mix
(Applied Biosystems) and a Ctcf-specific Taqman probe and
primers spanning the junction between Ctcf exons 9 and 10 as
follows: CTCF_mRNA_F1: 59-TGC CTT TGT CTG TTC CAA
GTG T-39, probe: 59-6FAM-ATT CAC CCG CCG GAA CAC
AAT GGC A-NFQ-39, mCTCF_mRNA_R1: 59-CAG CAC
AGT TAT CTG CAT GTC-39. Amplification of Gapdh was
performed in parallel reactions with primers and a Taqman probe
as follows: forward primer: 59-CCCGTAGACAAATGGT-
GAAGG-39, probe: 59- 6FAM-CGGTGTGAACG-
GATTTGGCCGTATT-3BHQ_1-39, and reverse primer: 59-
AAATGGCAGCCCTGGTGA-39. PCR was performed accord-
ing to the manufacturer’s instructions in 20 uL reactions, using
2 uL of 1:1 dilution of cDNA from RT reaction described above.
Standard ABI 7900 cycling conditions were followed. Sequence-
specific amplification was detected by FAM (reporter dye)
fluorescent signal during the amplification cycles. The standard
curve assay (as described by Applied Biosystems) with serial
dilutions of a standard was used for absolute quantification.
Following quantification, Ctcf-mRNA levels were normalized to
Gapdh expression. Each sample was assayed in triplicate; data
represents mean +/2 standard error.
Immunofluorescence and TUNEL assay
Blastocysts were cultured on pre-coated 0.1% gelatinized glass
slides or Lab-Tek permanox chamber slides (Nunc), fixed with
3.7% formaldehyde/PBS for 15 minutes and permeabilized with
0.5% Triton X-100/PBS at room temperature. The embryos were
washed with PBS/PVP (3 mg/ml) and incubated with a blocking
solution containing 10% NGS (ImmunoPure normal goat serum,
Pierce Biotechnology)/PBS/0.1% Triton X-100 for 1 hour at
room temperature followed by overnight incubation with a
primary rabbit monoclonal anti-CTCF antibody (Cell Signaling)
diluted 1:300 in 2% NGS/PBS/0.1% Triton X-100 at 4uC.
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were incubated with a secondary goat Texas red-conjugated anti-
rabbit antibody (1:200) (Jackson Laboratory) for 1 hour at room
temperature. After washing, slides were counterstained with DAPI.
Apoptosis was assessed using the DNA fragment end labeling kit
(FragEL, Calbiochem) following the manufacturer’s instructions.
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